GLP1R and myotonic dystrophy type 2: In the present study, we observed that six months of treatment with GLP-1 RAs dulaglutide or semaglutide leads to an improvement of LV GLS in subjects with DM2 with a high or very high risk for ASCVD or with ASCVD.